Article Information
History
- January 7, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Kosuke Yoshida1,2,3,
- Akira Yokoi1,2,*,
- Tomofumi Yamamoto3,
- Yusuke Hayashi3,
- Jun Nakayama3,
- Tsuyoshi Yokoi4,
- Hiroshi Yoshida5,
- Tomoyasu Kato6,
- Hiroaki Kajiyama1 and
- Yusuke Yamamoto3,*
- 1Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan
- 2Institute for Advanced Research, Nagoya University, Nagoya, Japan
- 3Laboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo, Japan
- 4Department of Drug Safety Sciences, Division of Clinical Pharmacology, Nagoya University Graduate School of Medicine, Nagoya, Japan
- 5Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan
- 6Department of Gynecology, National Cancer Center Hospital, Tokyo, Japan
- ↵*Corresponding authors: Akira Yokoi, M. D., Ph. D., Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine Tsuruma-cho 65, Showa-ku, Nagoya 466-8550, Japan, TEL: +81-52-744-2261, FAX: +81-52-744-2268, E-mail: ayokoi{at}med.nagoya-u.ac.jp, Yusuke Yamamoto, Ph.D., Laboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan, TEL: +81- 3-3452-2511, ext. 3664, FAX:+81-3-3543-9305, E-mail: yuyamamo{at}ncc.go.jp
Posted January 07, 2022.
Integrative transcriptomics analysis for uterine leiomyosarcoma identifies aberrant activation of cell cycle-dependent kinases and their potential therapeutic significance
